WT
NBIX icon

Whittier Trust’s Neurocrine Biosciences NBIX Stock Holding History

Whittier Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.23K Sell
53
-53
-50% -$7.86K ﹤0.01% 1151
2026
Q1 		$14K Buy
106
+53
+100% +$7.03K ﹤0.01% 1068
2025
Q4 		$7.28K Hold
53
– – ﹤0.01% 1184
2025
Q3 		$7.26K Hold
53
– – ﹤0.01% 1176
2025
Q2 		$6.66K Hold
53
– – ﹤0.01% 1299
2025
Q1 		$5.86K Hold
53
– – ﹤0.01% 1298
2024
Q4 		$7.23K Hold
53
– – ﹤0.01% 1301
2024
Q3 		$6.11K Sell
53
-90
-63% -$12.3K ﹤0.01% 1350
2024
Q2 		$19.7K Hold
143
– – ﹤0.01% 1094
2024
Q1 		$19.7K Hold
143
– – ﹤0.01% 1136
2023
Q4 		$18.8K Sell
143
-3
-2% -$345 ﹤0.01% 1110
2023
Q3 		$16.4K Buy
146
+3
+2% +$316 ﹤0.01% 1159
2023
Q2 		$13.5K Hold
143
– – ﹤0.01% 1210
2023
Q1 		$14.5K Hold
143
– – ﹤0.01% 1221
2022
Q4 		$17.1K Hold
143
– – ﹤0.01% 1182
2022
Q3 		$15K Hold
143
– – ﹤0.01% 1262
2022
Q2 		$14K Hold
143
– – ﹤0.01% 1254
2022
Q1 		$13K Sell
143
-147
-51% -$12.5K ﹤0.01% 1291
2021
Q4 		$25K Buy
290
+147
+103% +$13.5K ﹤0.01% 1129
2021
Q3 		$14K Hold
143
– – ﹤0.01% 1203
2021
Q2 		$14K Sell
143
-117
-45% -$11.2K ﹤0.01% 1218
2021
Q1 		$25K Buy
260
+117
+82% +$12.3K ﹤0.01% 1087
2020
Q4 		$14K Buy
143
+90
+170% +$8.69K ﹤0.01% 1112
2020
Q3 		$5K Hold
53
– – ﹤0.01% 1234
2020
Q2 		$6K Hold
53
– – ﹤0.01% 1138
2020
Q1 		$5K Hold
53
– – ﹤0.01% 1217
2019
Q4 		$6K Hold
53
– – ﹤0.01% 1217
2019
Q3 		$5K Buy
+53
New +$4.95K ﹤0.01% 1255

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Whittier Trust's NBIX Position: Q2 2026 in Review

Whittier Trust reduced its Neurocrine Biosciences (NBIX) stake by 50% in Q2 2026, selling an estimated $7.86K and leaving 53 shares worth $9.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1151.

Whittier Trust first reported a position in NBIX in Q3 2019 and has held it in 28 quarters since. The position peaked at $25K in Q4 2021. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Whittier Trust held 53 shares of Neurocrine Biosciences worth $9.23K as of Q2 2026.
  • Whittier Trust sold 53 Neurocrine Biosciences shares in Q2 2026, an estimated $7.86K.
  • Neurocrine Biosciences made up ﹤0.01% of Whittier Trust's portfolio in Q2 2026, its #1151 holding.
  • Whittier Trust first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Whittier Trust's Neurocrine Biosciences position peaked at $25K in Q4 2021.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Whittier Trust's 13F filing for Q2 2026, filed 28 Jul 2026.